Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

ss for the year ended June 30, 2011 compared to the net loss for the year ended June 30, 2010 was primarily attributable to a decrease in revenue recognized under Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca as a result of the successful completion of the research collaboration portion of the agreements.

RevenueRevenues in the quarter ended June 30, 2011 were $0.2 million, compared to $0.7 million for the same period in 2010.  For the year ended June 30, 2011, revenues were $1.5 million, compared to $14.2 million for year ended June 30, 2010.  

Costs and ExpensesFor the quarter ended June 30, 2011, total operating expenses were $4.7 million compared to $4.9 million for the comparable quarter of 2010.  For the year ended June 30, 2011, total operating expenses were $15.1 million compared to $17.2 million for the year ended June 30, 2010. The decreases in operating expenses for the respective periods is the result of reducing staffing levels pursuant to Palatin's strategic decision announced in September 2010.

Cash positionPalatin's cash and cash equivalents were $18.9 million as of June 30, 2011, compared to cash, cash equivalents and investments of $8.9 million at June 30, 2010, with current liabilities of $2.8 million as of June 30, 2011 compared to $2.4 million as of June 30, 2010.  

Palatin believes, based on its current operating plan, that its cash and cash equivalents will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on September 22, 2011 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments.  Individuals interested in listening to the conference call live can dial 1-800-281-7970 (domestic) or 1-913-312-0671 (international), pass code 9488233.  The webcas
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Grand Rapids, MI (PRWEB) November 22, 2014 ... the opportunity to simulate the proper management of ... training and test lung devices . Grand Rapids-based, ... Lung” plans to donate two of the respiratory ... $12,000 to $15,000 each. Grand Valley and Muskegon ...
(Date:11/21/2014)... Washington, USA (PRWEB) November 19, 2014 ... in our lives was shared with more than 200 ... and postgraduate students from the University of Otago Physics ... Grant . The Otago students, members of the university’s ... New Zealand in early September, giving children from small, ...
(Date:11/21/2014)... 20, 2014 The November 2014 issue ... an open access journal featuring the following articles:, ... to preserve photoresponsiveness in the retina , ... situ hybridization using chromogenic substrates in zebrafish , ... and protein electrophoresis , Nuclear LC3-positive puncta ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... CARLSBAD, Calif., Dec. 20 Ardea Biosciences,Inc. (Nasdaq: ... discovery and development of,small-molecule therapeutics for the treatment ... that it has entered into a,securities purchase agreement ... from the private placement of approximately 3.0,million newly ...
... WALTHAM, Mass., Dec. 20 Thermo Fisher,Scientific ... leader in serving science, today,announced it has ... chromatography consumables and related accessories, based in ... La-Pha-Pack will allow,Thermo Fisher to offer customers ...
... Continues Growth Strategy ... MOUNTAIN VIEW, Calif., Dec. 20 Pharsight,Corporation (Nasdaq: ... strategic,consulting, and regulatory services for optimizing clinical drug,development, ... audits of its Reporting and Analysis Services (RAS) ...
Cached Biology Technology:Ardea Biosciences Announces $40 Million Private Placement 2Ardea Biosciences Announces $40 Million Private Placement 3Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack 2Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack 3Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack 4Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 3Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 4
(Date:11/11/2014)... Inc., a Chicago -based digital forensics ... of Yaniv Schiff from Senior Computer Forensics ... role as Director, he will lead company efforts to ... provide leadership within the company,s digital forensics practice area.  ... Schiff joined Forensicon in 2006 and has ...
(Date:11/6/2014)... a team of Florida State University biologists could lead ... to and survive environmental swings such as droughts or ... of the journal The Plant Cell , sheds ... proteins) is organized in a cell and how plants ... on and others are turned off. , "If you ...
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Maize analysis yields whole new world of genetic science 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... with support from the National Institutes of Health ... dedicated to solving a wide range of challenging ... capable of 2.6 trillion mathematical operations per second, ... will be used to analyze everything from the ...
... Nonlinear Dynamics Ltd, a leading provider of bioinformatics ... OEM partnership with PerkinElmer, Inc. (NYSE: PKI), a ... and analytical solutions. , As detailed in a ... Nonlinear's full range of 1D, 2D and array ...
... By studying animals, Johns Hopkins researchers have discovered that ... on the brain and central nervous system, problems that ... elsewhere in the body. , Five monkeys infected with ... HIV, and treated with minocycline had less damage to ...
Cached Biology News:Supercomputer Dedicated To Bioengineering, Computational Biology Installed 2Supercomputer Dedicated To Bioengineering, Computational Biology Installed 3Antibiotic might fight HIV-induced neurological problems 2Antibiotic might fight HIV-induced neurological problems 3
... with a modular approach to instrument control, ... Plus NDS family provides modular software components ... management, giving you the flexibility to choose ... now and that can grow as your ...
... Process Control at its Best: ... Real-Time Monitoring, Online Changes & comprehensive ... range of parameters auch as pH, ... are accessible and changeable online. Profiles, ...
... designed for immunological studies, vaccine development, ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive Epitope ... Probe Content Probe content is ...
... are custom designed to meet your needs. ... 8,455 features per array (2 arrays/1" x ... array (1 array/slide). Features ... - This extended length delivers higher sensitivity ...
Biology Products: